Actelion 9-months net income leaps 21%; hikes full year forecast

21 October 2016

Swiss biotech firm Actelion (SIX: ATLN) has reported results for the first nine months of 2016, showing that net revenues increased 17% (+14 at constant exchange rates) to 1.79 billion Swiss francs ($1.82 billion), with net income up 29% (+21% CER) to 581 million francs, and diluted earnings per share at 5.37 francs, a rise of 35% (+27% CER).

The company indicated that core operating income growth this year is now expected to be in the mid-teen percentage range, at constant exchange rates, up from a previous estimate of a low-teen percentage increase.

Third-quarter revenue rose 15% to 606 million francs, beating the expectations of analysts polled by Reuters for revenue of 591 million francs.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK